{"schema_version":"secwatch.filing_event.v1","accession":"0001087294-26-000064","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-08-28T21:08:50+00:00","discovered_at":"2026-08-28T21:10:00.443435+00:00","generated_at":"2026-08-28T21:10:06.061936+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cumberland delays release of FIGHT DMD ifetroban long-term data; no new timeline","bullets":["Phase 2 FIGHT DMD open-label extension long-term safety/efficacy data for ifetroban not yet available.","Company no longer expects to present data in August 2026 as stated at PPMD conference on June 26, 2026.","Data was originally expected at Parent Project Muscular Dystrophy annual conference in Orlando.","Cumberland will present at a future date when data becomes available; no revised timeline given.","Ifetroban is an oral candidate for Duchenne muscular dystrophy heart disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001087294-26-000064","json":"https://secwatch.observer/filing/0001087294-26-000064.json","markdown":"https://secwatch.observer/filing/0001087294-26-000064.md","text":"https://secwatch.observer/filing/0001087294-26-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000064/0001087294-26-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000064/cpix-20260828.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-28T21:10:06.061936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}